乙酮,1-(1-甲基-1H-咪唑-4-基)-(9CL) | 129003-87-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 乙酮,1-(1-甲基-1H-咪唑-4-基)-(9CL)
• 中文别名: 4-乙酰基-1-甲基-1H-咪唑
• 英文名称: 1-(1-methyl-1H-imidazol-4-yl)ethanone
• 英文别名: 1-(1-Methyl-lH-imidazol-4-yl)-ethanone；4-acetyl-1-methyl-1H-imidazole；1-(1-methylimidazol-4-yl)ethanone
• CAS: 129003-87-8
• 化学式: C₆H₈N₂O
• 分子量: 124.142
• InChiKey: NWXBHGNKHIRMAV-UHFFFAOYSA-N

物化性质

• 沸点：
  289℃
• 密度：
  1.11
• 闪点：
  128℃

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  乙酮,1-(1-甲基-1H-咪唑-4-基)-(9CL) 、 草酸二乙酯 以to give ethyl 4-(1-methyl-1H-imidazol-4-yl)-2,4-dioxobutanoate (1.122 g, 83%) as a solid的产率得到4-(1-methyl-1H-imidazol-4-yl)-2,4-dioxobutanoic acid ethyl ester
  参考文献：
  名称：

  Amidopyrazole Derivative

  摘要：

  提供了一种血小板凝血抑制剂，它既不抑制COX-1也不抑制COX-2。该抑制剂是由通式（I）表示的化合物：其中Ar1和Ar2独立地表示一个5-或6-成员的芳香杂环基团，可选地取代1至3个取代基，或一个苯基，可选地取代1至3个取代基；R1表示较低的酰基，羧基，较低的烷氧羰基，较低的烷氧基，较低的烷基，可选地取代1或2个取代基的氨基甲酰基，可选地取代1或2个取代基的草酰基，可选地取代1或2个取代基的氧代草酰基，可选地取代1或2个取代基的氨基，可选地取代1或2个取代基的4-至7-成员脂环杂环基团，可选地取代1或2个取代基的苯基，或可选地取代1至3个取代基的5-或6-成员芳香杂环基团；R2表示氢原子，卤素基或类似物。

  公开号：

  US20070219210A1
• 作为产物：
  描述：

  4-(1-methoxyethenyl)-1-methyl 1-methyl-1H-imidazole 在 silica gel 、 二氯甲烷 作用下， 以 乙腈 、 水 为溶剂， 反应 20.0h， 以to give 1-(1-methyl-1H-imidazol-4-yl)ethanone B.50 (70 mg, 38%) as a white solid的产率得到乙酮,1-(1-甲基-1H-咪唑-4-基)-(9CL)
  参考文献：
  名称：

  ALKYNYL ALCOHOLS AS KINASE INHIBITORS

  摘要：

  所选化合物对于预防和治疗炎症和炎症性疾病（如NIK介导的疾病）有效。本发明涵盖新的化合物、类似物、前药和其药学上可接受的盐、制药组合物和预防和治疗涉及炎症等疾病和其他疾病或病症的方法。

  公开号：

  US20110086834A1

文献信息

• FLUORENE-TYPE COMPOUND, PHOTOPOLYMERIZATION INITIATOR COMPRISING SAID FLUORENE-TYPE COMPOUND, AND PHOTOSENSITIVE COMPOSITION CONTAINING SAID PHOTOPOLYMERIZATION INITIATOR
  申请人：Daito Chemix Corporation

  公开号：US20150259321A1

  公开（公告）日：2015-09-17

  According to an embodiment of the present invention, there is provided a novel fluorene-based compound and a photopolymerization initiator using the fluorene-based compound. The fluorene-based compound according to an embodiment of the present invention is represented by the general formula (1). A photopolymerization initiator having additionally high sensitivity can be provided by using the fluorene-based compound. In addition, a photopolymerization initiator that can impart additionally excellent characteristics can be provided by appropriately selecting, for example, a substituent.

  根据本发明实施例，提供了一种新的基于芴的化合物和使用该基于芴的化合物的光聚合引发剂。根据本发明实施例，基于芴的化合物由通式（1）表示。通过使用基于芴的化合物，可以提供具有更高灵敏度的光聚合引发剂。此外，通过适当选择例如取代基，可以提供具有额外优异特性的光聚合引发剂。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton Kenneth

  公开号：US20120289493A1

  公开（公告）日：2012-11-15

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类为钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该化合物的结构由式I给出： 其中Q、R1、X1、X2、Y和R2如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• [EN] ALKYNYL ALCOHOLS AS KINASE INHIBITORS<br/>[FR] ALCOOLS D'ALCYNYLE UTILISÉS COMME INHIBITEURS DE KINASES
  申请人：AMGEN INC

  公开号：WO2009158011A1

  公开（公告）日：2009-12-30

  Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

  选定的化合物对预防和治疗炎症和炎症性疾病，如NIK介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药及其药用可接受的盐，以及用于预防和治疗涉及炎症等疾病和其他疾病或病症的药物组合物和方法。
• Organic compounds
  申请人：Ksander Michael Gary

  公开号：US20070049616A1

  公开（公告）日：2007-03-01

  The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种I式化合物：所述化合物是醛固酮合成酶和芳香化酶的抑制剂，因此可用于治疗由醛固酮合成酶或芳香化酶介导的疾病或疾病。因此，I式化合物可用于治疗低钾血症、高血压、充血性心力衰竭、心房颤动、肾功能衰竭，特别是慢性肾功能衰竭、再狭窄、动脉粥样硬化、X综合征、肥胖、肾病、心肌梗死后、冠心病、炎症、胶原蛋白增生、纤维化如心脏或心肌纤维化以及高血压和内皮功能障碍后的重塑，男性乳房发育过大、骨质疏松症、前列腺癌、子宫内膜异位症、子宫肌瘤、功能性子宫出血、子宫内膜增生、多囊卵巢综合征、不孕症、纤维囊性乳腺疾病、乳腺癌和纤维囊性乳房病。最后，本发明还提供了一种药物组合物。